Skye Bioscience, Inc.
SKYE
$3.29
-$0.26-7.32%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -58.74% | -13.92% | -150.02% | 50.67% | -57.44% |
| Total Depreciation and Amortization | 5.47% | 1.20% | 165.61% | 121.48% | 7.97% |
| Total Amortization of Deferred Charges | -- | -- | -100.00% | -55.45% | 5.52% |
| Total Other Non-Cash Items | -11.73% | -2.89% | 186.38% | -225.89% | 56.44% |
| Change in Net Operating Assets | 1,129.02% | 46.93% | -180.26% | 169.61% | -20.97% |
| Cash from Operations | -16.99% | -12.39% | -55.30% | 25.81% | -50.67% |
| Capital Expenditure | 100.00% | 87.40% | 96.71% | -4,572.00% | -915.63% |
| Sale of Property, Plant, and Equipment | -- | -- | 92.86% | -- | -100.00% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 6.70% | -- | -- | -- | -- |
| Cash from Investing | 7.45% | -14,269.25% | 106.25% | -4,347.69% | -102.85% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -- | 100.00% | -102.45% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -2.68% | -172.31% | -20.41% | 27.26% | -111.23% |